SUSTAINABLE DEVELOPMENT
Innovate. Sustain. Transform.
Save up to 30% on top Physical Sciences & Engineering titles!
Resistance in Hematologic Malignancies and Cancer
- 1st Edition - October 29, 2024
- Editors: Lucia Messingerova, Albert Breier
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 2 1 7 9 0 - 6
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 1 7 9 1 - 3
Resistance in Hematologic Malignancies and Cancer brings together the molecular, cellular, and biochemical basis/principles of various mechanisms of resistance to treatment… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteResistance in Hematologic Malignancies and Cancer brings together the molecular, cellular, and biochemical basis/principles of various mechanisms of resistance to treatment in hematologic malignancies.
Even though main mechanisms of resistance are the same in different types of tumours there are specific signalling pathways involved in resistance in hematological malignancies and of course specific treatments
In 11 chapters, Resistance in Hematologic Malignancies and Cancer describes the development of treatment resistance in hematological malignancies, the role of MiRNA in resistance, the role of the immune system in resistance prediction, as well as the latest knowledge from clinical research.
It gives insight in the complex information about different mechanisms linkage in final loss of cell sensitivity to drug treatment, the orientation in metabolic pathways that could be involved in depressed leukemia cell resistance to drugs and gives information about causes of drug resistance in leukemia cells.
By the multidisciplinary approach of the processing this book is a valuable resource for both health professionals, scientists and researchers, health practitioners, students, but will also enable members of the general professional public to orientate themselves in issues that are not directly in their area of expertise
- Describes the different mechanisms of resistance; cooperation in net resistance to antileukemic drugs
- Provides hallmark information about cell regulation pathways in drug resistance development
- Brings information about causes of drug resistance in leukemia and hematologic malignancies including lymphoma and myeloma
Researchers and graduate students in cancer research Medical oncologist and Pharmacologist. Clinical researchers, Undergraduate and postgraduate courses in medicine, biochemistry, pharmacy, biology
- Resistance in Hematologic Malignancies and Cancer
- Cover image
- Title page
- Table of Contents
- Copyright
- Cover Image Insert
- Aims and Scope for Series “Cancer Sensitizing Agents for Chemotherapy”
- About the Series Editor
- Acknowledgments
- Aims and Scope of Volume
- Volume Editor Biography
- Preface
- Contributors
- Chapter 1 Drug classification for the treatment of hematologic malignancies
- Abstract
- Keywords
- Conflict of interest
- Introduction
- Chemotherapeutic drugs
- Alkylating agents
- Antimetabolites
- Natural alkaloids with antitubulin activity
- Cytotoxic antibiotics
- Fixed-dose combination drugs
- Small-molecule anticancer drugs
- Tyrosine kinase inhibitors
- Multikinase inhibitors
- Phosphatidylinositol 3-kinase inhibitors
- Enzyme inhibitors
- Smoothed receptor antagonists
- Various protein inhibitors
- Protein translation inhibitors
- Immunomodulators
- Macromolecule anticancer drugs
- Monoclonal antibodies
- Bispecific antibodies
- Antibody-drug conjugates
- Recombinant immunotoxins
- Enzymes
- CAR-T cells
- Conclusions
- References
- Chapter 2 Reduce drug uptake in the development of resistance
- Abstract
- Keywords
- Conflict of interest
- Introduction
- Drug uptake mechanisms
- Drug uptake as resistance mechanisms
- Drug transporters’ genetic variants in anticancer drug response
- Exploring the role of radiopharmaceuticals in assessing MDR
- Strategies to overcome drug uptake-mediated resistance
- Conclusions and future perspectives
- References
- Chapter 3 The role of enhanced drug efflux in drug resistance
- Abstract
- Keywords
- Conflict of interest
- Introduction
- Characterization and structure of membrane transporters (transporter ability to efflux drugs)
- ABC transporters
- The ATP-binding cassette transporter superfamily
- ABCA subfamily
- ABCB subfamily
- ABCC subfamily
- ABCD subfamily
- ABCE and ABCF subfamilies
- ABCG subfamily
- Substrate specificity of P-gp, MRP1, and BCRP, which are known to cause MDR
- Regulatory pathways of ABC transporters
- Role of ABC transporters in hematological malignancies
- Different ways to prevent or revert drug resistance mediated by ABC transporters
- Conclusion and future perspectives
- References
- Chapter 4 MicroRNAs and other noncoding RNA species in diagnostics, prognostics and therapy response of blood cancers
- Abstract
- Keywords
- Conflict of interest
- Introduction
- MiRNAs and other ncRNAs biogenesis and their regulatory roles
- Role of miRNAs in hematopoiesis and hematological malignancies
- MiRNAs in leukemia
- MiRNAs across lymphoma subtypes
- MiRNAs in myeloma
- MiRNAs in monoclonal gammopathy of undetermined significance (MGUS)
- Future perspectives
- Conclusion
- References
- Chapter 5 Switching between autophagy and apoptosis prosurvival and prodeath balance in leukemia cells
- Abstract
- Keywords
- Conflict of interest
- Introduction
- Apoptosis
- Apoptosis deregulation in leukemia
- Apoptosis deregulation and treatment resistance
- Autophagy
- Autophagy deregulation in leukemia
- Targeting autophagy to modulate chemoresistance in leukemia
- Conclusion
- References
- Chapter 6 The role of UPR signaling pathways in cancer cell resistance to chemotherapy
- Abstract
- Keywords
- Conflict of interest
- Introduction
- Stress receptor of endoplasmic reticulum
- Inositol-requiring enzyme 1α
- Protein kinase R-like endoplasmic reticulum kinase
- Activating transcription factor 6
- Crosstalk between cellular response to ER stress and drug resistance of cancer cells
- Glucose-regulated protein 78/binding immunoglobulin protein in cancer and drug resistance
- ATF6 pathway in cancer drug resistance
- PERK and IRE1α pathways in cancer drug resistance
- Targeted treatment of malignant tumors focused on UPR
- UPR-induced chemotherapy resistance
- UPR as a therapeutic target
- Conclusions for future research orientation
- References
- Chapter 7 Altered cell cycle regulation in the development of resistance
- Abstract
- Keywords
- Conflict of interest
- Introduction
- Cell cycle regulation
- Cell cycle genetic abnormalities in drug resistance
- Cell cycle reprogramming in drug tolerance and dormancy
- Influence of cell cycle on chemotherapy
- Influence of cell cycle on radiotherapy
- Conclusion and future perspectives
- References
- Chapter 8 Deregulation of drug metabolizing enzymes and transporters in cancer via altered aryl hydrocarbon receptor signaling
- Abstract
- Keywords
- Conflict of interest
- Introduction
- AhR-regulated phase I enzymes and cancer
- AhR-regulated phase II enzymes and cancer
- AhR, drug transport and cancer
- Conclusion
- References
- Chapter 9 Immune system in resistance prediction
- Abstract
- Keywords
- Conflict of interest
- Introduction
- Tumor microenvironment and tumor-infiltrating lymphocytes
- Immune checkpoints and PD-L1 expression
- Cytokine signatures
- Tumor necrosis factor-alpha
- Interferon-γ
- Interleukin-6
- Interleukin-8
- Transforming growth factor-β
- Other IL family members
- Conclusion
- References
- Chapter 10 Mechanisms of resistance of antibody-drug conjugates—Obstacles to overcome
- Abstract
- Keywords
- Conflict of interest
- Introduction
- Historical development
- Structure of the ADCs
- Mechanisms of resistance
- Antigen expression
- Payload related resistance
- Changed internalization
- Lysosomal dysfunction
- Upregulation of drug efflux pumps
- Activation of signaling pathways
- Apoptotic dysregulation
- Challenges and future perspectives
- Conclusion
- References
- Chapter 11 Resistance to chimeric antigen receptor T cells (CAR-T)
- Abstract
- Keywords
- Conflict of interest
- Introduction
- CAR-T cell therapy
- Clinical applications in hematological malignancies
- Resistance to the FDA approved therapies
- Conclusion
- References
- Index
- No. of pages: 326
- Language: English
- Edition: 1
- Published: October 29, 2024
- Imprint: Academic Press
- Hardback ISBN: 9780443217906
- eBook ISBN: 9780443217913
LM
Lucia Messingerova
After completing her studies, Dr. Messingerova started working at the Slovak Technical University, Faculty of Chemical and Food Technology, as well as at the Slovak Academy of Sciences in the Centre for Biosciences, where she leads a team dealing with the development of resistance to hypomethylating agents (HMAs) in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In her work, she focuses on changes in apoptotic pathways, transport, and metabolism of HMAs in sensitive and resistant AML cell lines. The goal of her team's work is to identify an easily and quickly detectable marker of response to HMA treatment, since it is known that after the failure of this treatment in patients unsuitable for intensive therapy, only the possibility of inclusion in clinical trials or palliative care remains.
Affiliations and expertise
Slovak Academy of Sciences, Centre of Bioscineces, Institute of Molecular Physiology and Genetics, Bratislava, SlovakiaAB
Albert Breier
Albert Breier is Professor at the Faculty of Chemical and Food Technology, Slovak University of Technology, and Chief Research fellow at the Institute of Molecular Physiology and Genetics, Centre of Biosciences, Slovak Academy of Sciences, Bratislava, Slovak Republic, Chief Research Fellow. He holds a PhD in Biochemistry and is the author of more than 130 scientific publications that were more than 1200 times cited. His research interest is anti-cancer agents
Affiliations and expertise
Head of Biochemistry and Microbiology Department, Faculty of Chemical and Food Technology, Slovak University of Technology, Bratislava, SlovakiaRead Resistance in Hematologic Malignancies and Cancer on ScienceDirect